LGVN (Longeveron) Interest Income : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longeveron Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Longeveron's interest income for the three months ended in Dec. 2024 was $0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Longeveron Interest Income Historical Data

The historical data trend for Longeveron's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron Interest Income Chart

Longeveron Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Income

Get a 7-Day Free Trial

Longeveron Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Income	Get a 7-Day Free Trial															-	-	-	-	-

Longeveron Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Longeveron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136

Website

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Executives

Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Hashad Mohamed Wa'el Ahmed	officer: Chief Executive Officer	SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare	director, officer: Chief Scientific Officer	C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Cathy Ross	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Jeffrey Pfeffer	director
Lisa Locklear	officer: Chief Financial Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova	officer: Chief Medical Officer	1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo	officer: CFO and Treasurer	1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Kwan-hong Christopher Min	officer: Chief Medical Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green	officer: CEO	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr	officer: General Counsel, Secretary	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer	director, 10 percent owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136